The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors.
 
Jaafar Bennouna
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Daichii; Daichii; Ipsen; Janssen Oncology; MSD Oncology; Novartis; SERVIER
Consulting or Advisory Role - AMGEN; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Françoise Shneiker
Employment - XENOTHERA
Leadership - XENOTHERA
Stock and Other Ownership Interests - XENOTHERA
Consulting or Advisory Role - XENOTHERA
Travel, Accommodations, Expenses - XENOTHERA
 
Jean Yves BLAY
No Relationships to Disclose
 
Ahmad Awada
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Eisai; Genomic Health; Hengrui Therapeutics; Innate Pharma; Ipsen; LEO Pharma; Lilly; Menarini; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
 
Firas Bassissi
Employment - XENOTHERA
Leadership - XENOTHERA
Stock and Other Ownership Interests - XENOTHERA
Travel, Accommodations, Expenses - XENOTHERA
 
Raffaele Ratta
Honoraria - Advanced Accelerator Applications; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; MSD Oncology; Pfizer
Consulting or Advisory Role - Astellas Pharma; Ipsen; MSD; Pfizer
Travel, Accommodations, Expenses - Ipsen; Janssen; MSD Oncology
 
Jean-Pierre Delord
No Relationships to Disclose